JP2009185004A - Agent for easing metabolic syndrome - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide an agent for easing metabolic syndrome that can be safely taken in over a long period and serves as a promoter for reducing body fat, to promote the reduction of body fat and to get rid of obesity, a promoter for lipid metabolism to promote lipid metabolism and to increase lipid combustion, an agent for preventing or treating liver disease to prevent or treat liver disease such as fatty liver and an appetite suppressant to properly suppress appetite and to suppress overeating. <P>SOLUTION: Tea blossom of tea or its extract is used as an active ingredient of the promoter for reducing body fat, the promoter for lipid metabolism, the agent for preventing or treating liver disease and the appetite suppressant. <P>COPYRIGHT: (C)2009,JPO&INPIT

Description

  The present invention relates to a body fat reduction promoter that promotes the reduction of body fat and eliminates obesity, a lipid metabolism promoter that promotes lipid metabolism and enhances fat burning, and prevents or treats liver disorders such as fatty liver The present invention relates to a preventive or therapeutic agent for hepatic disorder, and an eating inhibitor for appropriately suppressing food intake by appropriately suppressing appetite.

  In European and American advanced countries including Japan, obesity tends to increase significantly due to over-nutrition due to excessive intake of animal protein, animal fat, instant food, fast food, etc., and further lack of exercise.

  Obesity is generally defined as obesity when fat is excessively stored or accumulated in the body and the BMI value is 25 or more.

  Obesity is one of the risk factors for diabetes, hypertension, arteriosclerosis and hyperlipidemia, and is also said to contribute to hyperuricemia, cholelithiasis and gout. In particular, the symptoms of visceral fat type obesity combined with multiple of these are called metabolic syndrome, and the patient population is explosively increasing mainly in developed countries such as Japan, and measures in various forms are required. It has been.

  Elimination of obesity includes diet therapy based on calorie restriction, exercise therapy based on energy consumption, therapy based on intake of foods and beverages or pharmaceuticals that are said to have an effect of eliminating obesity, or combinations thereof. However, although diet and exercise therapy are expected to have a positive effect, these methods need to be continued for a long period of time, and those who cannot tolerate this are those who are often found in transient weight loss. You will have the problem of rebound.

  In addition, as a therapy based on the intake of pharmaceuticals, a method using an antifeedant that suppresses appetite and reduces food intake is known. Such therapy uses antidepressants such as adrenergic agonists or serotonin agonists, but is limited to patients with indications such as being used only in patients with severe obesity that are difficult to diet. There is also a problem in terms of drug dependence.

  Also, those who are diagnosed with obesity have a high proportion of fatty liver. Fatty liver refers to a state in which fat droplets occupy more than one-third of the liver lobule, and is a factor inducing cirrhosis and hepatitis. Therefore, in the case of obese patients with fatty liver, it is also considered important to improve fatty liver.

  In addition, substances with multiple functions such as reduction of body fat, promotion of lipid metabolism, suppression of feeding, improvement of fatty liver, etc. are not limited to the elimination of obesity, but metabolic syndrome ( It can also be effective in improving visceral fat syndrome.

On the other hand, tea ( Camellia sinensis , also known as: Thea sinensis ) is an evergreen tree that is widely grown or grown in Southeast Asia and East Asia such as India, Sri Lanka, Indonesia, China, and Japan. It is classified as a plant belonging to ( TheaceaeCamellia ). With regard to tea, young leaves are conventionally used as a raw material for tea beverages such as green tea, oolong tea and black tea. The tea leaves contain polyphenols effective for eliminating active oxygen and the like, and contain saponin compounds having anti-inflammatory and anti-allergic effects (Non-patent Document 1 and Patent Document 1). Etc.) has been reported, and much research has been conducted on the tea leaf part or its extract as a functional food material.

More recently, research on the flower part of the tea that has not attracted much attention has been conducted, and the extract of the flower part of the tea or a specific saponin compound contained in the extract contains neutral fat. It has been reported that it has an absorption inhibitory action, a sugar absorption inhibitory action, or a gastric mucosa protective action (Patent Document 2). However, with regard to the tea flower extract, only the function of suppressing the bioabsorption of neutral fat and sugar as described above has been clarified. There are no reports about the effects on liver damage and the presence or absence of feeding suppression effects.
Japanese Unexamined Patent Publication No. 7-61998 JP 2006-70018 A Kitagawa I. , Hori K. , Motozawa T. , Murakami T. , Yoshikawa M. Chem. Pharm. Bull. , 46, 1901-1906 (1998)

  The present invention is a body fat reduction promoter that promotes the reduction of body fat and eliminates obesity that can be safely and over a long period of time, and promotes lipid metabolism to promote lipid metabolism and enhance lipid combustion Providing an agent, a preventive or therapeutic agent for hepatic disorder for preventing or treating hepatic disorders such as fatty liver, and an eating inhibitor for suppressing excessive food intake by appropriately suppressing appetite Objective.

  The present inventors diligently studied to solve the above-mentioned problems. As a result, the cha flower part or its extract, which is highly safe and can be used as a food material, has a function of promoting reduction of body fat, lipid metabolism. The present invention has been found to have an action to promote the action, an action to prevent or treat liver disorders such as fatty liver, and an action to moderately reduce food intake. The present invention has been developed through further studies based on such findings.

That is, this invention provides the invention of the aspect hung up below as a use regarding the body fat reduction promotion of the flower part of a tea, or its extract.
Item 1-1. A body fat reduction promoter comprising tea flower or its extract as an active ingredient.
Item 1-2. Item 11. The body fat reduction promoter according to Item 1-1, which is for reducing accumulated body fat.
Item 1-3. Item 11. The body fat reduction promoter according to Item 1-1 or 1-2, wherein the extract is an extract obtained by extracting a flower part of tea with water or a hydrous lower alcohol.
Item 1-4. A composition for promoting body fat reduction, comprising a flower part of tea or an extract thereof.
Item 1-5. Item 5. The composition for promoting body fat reduction according to Item 1-4, which is a food composition or a pharmaceutical composition.
Item 1-6. Item 1-4, or a daily intake unit or daily dosage unit, containing 0.5 to 25000 mg of cha flower or 0.1 to 5000 mg of cha flower extract in terms of dry weight The composition for reducing body fat according to 1-5.
Item 1-7. A food composition comprising the body fat reduction promoter according to any one of Items 1-1 to 1-3, and a food material and / or food additive.
Item 1-8. Item 8. The food composition according to Item 1-7, which is used for promoting body fat reduction.
Item 1-9. Item 10. The food composition according to Item 1-7 or 1-8, comprising 0.005 to 99% by weight of a tea flower part or 0.001 to 70% by weight of an extract of a tea flower part in terms of dry weight.
Item 1-10. Any one of Items 1-7 to 1-9, containing 0.5 to 25000 mg of tea flower or 0.1 to 5000 mg of tea flower extract in terms of dry weight per daily intake unit Food composition according to crab.
Item 1-11. Item 11. The food composition according to any one of Items 1-7 to 1-10, which is a beverage or a supplement type food.
Item 1-12. Item 11. The food composition according to Item 1-11, which is a tablet, capsule, powder, or granule.
Item 1-13. Item 10. The food composition according to Item 1-11, which is a beverage containing 0.005 to 25 w / v% of the flower part of tea or 0.001 to 5 w / v% of the extract of the flower part of the tea in terms of dry weight.
Item 1-14. Item 11. The food composition according to Item 1-11, which is a supplement-type food containing 0.25 to 99% by weight of a tea flower part or 0.05 to 70% by weight of an extract of a tea flower part in terms of dry weight.
Item 1-15. Item 4. A pharmaceutical composition comprising the body fat reduction promoter according to any one of Items 1-1 to 1-3, and a pharmaceutically acceptable carrier and / or additive.
Item 1-16. Item 15. The pharmaceutical composition according to Item 1-15, which is used for promoting body fat reduction.
Item 1-17. Item 15. The pharmaceutical composition according to Item 1-15 or 1-16, comprising 0.005 to 70% by weight of a tea flower part or 0.001 to 70% by weight of an extract of a tea flower part in terms of dry weight.
Item 1-18. Item 1-15 to 1-17, formulated to contain 0.5 to 25000 mg of tea flower or 0.1 to 5000 mg of tea flower extract in dry weight per daily dosage unit A pharmaceutical composition according to any one of the above.

This invention provides the invention of the aspect hung up below as a use regarding the lipid metabolism promotion of the flower part of a tea, or its extract.
Item 2-1. A lipid metabolism promoter comprising tea flower or an extract thereof as an active ingredient.
Item 2-2. Item 2. The lipid metabolism promoter according to item 2-1, wherein the extract is an extract obtained by extracting a flower part of tea with water or a hydrous lower alcohol.
Item 2-3. A composition for promoting lipid metabolism, comprising tea flower or an extract thereof.
Item 2-4. Item 4. The composition for promoting lipid metabolism according to Item 2-3, which is a food composition or a pharmaceutical composition.
Item 2-5. Item 2-3 or so that it contains 0.5 to 25000 mg of tea flower part or 0.1 to 5000 mg of tea flower extract in terms of dry weight per daily intake unit or daily dosage unit The composition for promoting lipid metabolism according to 2-4.
Item 2-6. A food composition comprising the lipid metabolism promoter according to Item 2-1 or 2-2, and a food material and / or food additive.
Item 2-7. Item 7. The food composition according to Item 2-6, which is used for lipid metabolism promotion.
Item 2-8. Item 8. The food composition according to Item 2-6 or 2-7, comprising 0.005 to 99% by weight of a tea flower part or 0.001 to 70% by weight of an extract of a tea flower part in terms of dry weight.
Item 2-9. Any of Items 2-6 to 2-8, which is made to contain 0.5-25000 mg of tea flower or 0.1-5000 mg of tea flower extract in terms of dry weight per daily intake unit Food composition according to crab.
Item 2-10. Item 10. The food composition according to any one of Items 2-6 to 2-9, which is a beverage or a supplement type food.
Item 2-11. Item 10. The food composition according to Item 2-10, which is a tablet, capsule, powder, or granule.
Item 2-12. Item 10. The food composition according to Item 2-10, which is a beverage containing 0.005 to 25 w / v% of a tea flower part or 0.001 to 5 w / v% of an extract of a tea flower part in terms of dry weight.
Item 2-13. Item 10. The food composition according to Item 2-10, which is a supplement-type food containing 0.25 to 99% by weight of a tea flower part or 0.05 to 70% by weight of an extract of a tea flower part in terms of dry weight.
Item 2-14. Item 3. A pharmaceutical composition comprising the lipid metabolism promoter according to Item 2-1 or 2-2, and a pharmaceutically acceptable carrier and / or additive.
Item 2-15. Item 15. The pharmaceutical composition according to Item 2-14, which is used for lipid metabolism promotion.
Item 2-16. Item 16. The pharmaceutical composition according to Item 2-14 or 2-15, comprising 0.005 to 70% by weight of a tea flower part or 0.001 to 70% by weight of an extract of a tea flower part in terms of dry weight.
Item 2-17. Item 2-14 to 2-16, formulated to contain 0.5 to 25000 mg of cha flower or 0.1 to 5000 mg of tea flower extract in dry weight per daily dosage unit A pharmaceutical composition according to any one of the above.

This invention provides the invention of the aspect hung up below as a use regarding the prevention or treatment of the liver damage of the flower part of a tea, or its extract.
Item 3-1. A preventive or therapeutic agent for liver damage, comprising tea flower or its extract as an active ingredient.
Item 3-2. Item 3. The preventive or therapeutic agent for liver injury according to Item 3-1, wherein the extract is an extract obtained by extracting a flower part of tea with water or a hydrous lower alcohol.
Item 3-3. A composition for preventing or treating liver damage, comprising tea flower or an extract thereof.
Item 3-4. Item 4. The composition for preventing or treating liver damage according to Item 3-3, which is a food composition or a pharmaceutical composition.
Item 3-5. Item 3-3 or which is manufactured to contain 0.5 to 25000 mg of tea flower part or 0.1 to 5000 mg of tea flower extract in terms of dry weight per daily intake unit or daily dosage unit A composition for preventing or treating liver damage according to 3-4.
Item 3-6. Item 3. A food composition comprising the preventive or therapeutic agent for liver damage according to item 3-1 or 3-2, and a food material and / or food additive.
Item 3-7. Item 7. The food composition according to Item 3-6, which is used for preventing or treating liver damage.
Item 3-8. Item 8. The food composition according to Item 3-6 or 3-7, containing 0.005 to 99% by weight of a tea flower part or 0.001 to 70% by weight of an extract of a tea flower part in terms of dry weight.
Item 3-9. Any one of Items 3-6 to 3-8, which is made to contain 0.5-25000 mg of tea flower or 0.1-5000 mg of tea flower extract in terms of dry weight per daily intake unit Food composition according to crab.
Item 3-10. Item 10. The food composition according to any one of Items 3-6 to 3-9, which is a beverage or a supplement type food.
Item 3-11. Item 10. The food composition according to Item 3-10, which is a tablet, capsule, powder, or granule.
Item 3-12. Item 10. The food composition according to Item 3-10, which is a beverage containing 0.005 to 25 w / v% tea flower part or 0.001 to 5 w / v% tea flower extract in terms of dry weight.
Item 3-13. Item 10. The food composition according to Item 3-10, which is a supplement-type food containing 0.25 to 99% by weight of a tea flower part or 0.05 to 70% by weight of an extract of a tea flower part in terms of dry weight.
Item 3-14. Item 3. A pharmaceutical composition comprising the preventive or therapeutic agent for liver injury according to Item 3-1 or 3-2 and a pharmaceutically acceptable carrier and / or additive.
Item 3-15. Item 15. The pharmaceutical composition according to Item 3-14, which is used for preventing or treating liver damage.
Item 3-16. Item 16. The pharmaceutical composition according to Item 3-14 or 3-15, comprising 0.005 to 70% by weight of a tea flower part or 0.001 to 70% by weight of an extract of a tea flower part in terms of dry weight.
Item 3-17. Item 3-14 to 3-16, formulated to contain 0.5 to 25000 mg of cha flower or 0.1 to 5000 mg of tea flower extract in dry weight per daily dosage unit A pharmaceutical composition according to any one of the above.

This invention provides the invention of the aspect hung up below as a use regarding the feeding suppression of the flower part of a tea, or its extract.
Item 4-1. An antifeedant containing tea flower or its extract as an active ingredient.
Item 4-2. Item 5. The feeding inhibitor according to Item 4-1, wherein the extract is an extract obtained by extracting a flower part of tea with water or a hydrous lower alcohol.
Item 4-3. A composition for suppressing feeding, comprising a flower part of tea or an extract thereof.
Item 4-4. Item 4. The composition for inhibiting feeding according to Item 4-3, which is a food composition or a pharmaceutical composition.
Item 4-5. Item 4-3, which is manufactured to contain 0.5 to 25000 mg of tea flower part or 0.1 to 5000 mg of tea flower extract in terms of dry weight per daily intake unit or daily dosage unit The composition for feeding suppression according to 4-4.
Item 4-6. A food composition comprising the feeding inhibitor according to Item 4-1 or 4-2, and a food material and / or food additive.
Item 4-7. Item 7. The food composition according to item 4-6, which is used for eating suppression.
Item 4-8. Item 8. The food composition according to Item 4-6 or 4-7, containing 0.005 to 99% by weight of a tea flower part or 0.001 to 70% by weight of an extract of a tea flower part in terms of dry weight.
Item 4-9. Any one of Items 4-6 to 4-8, which is made to contain 0.5-25000 mg of tea flower part or 0.1-5000 mg of tea flower part extract in terms of dry weight per daily intake unit Food composition according to crab.
Item 4-10. Item 10. The food composition according to any one of Items 4-6 to 4-9, which is a beverage or a supplement type food.
Item 4-11. Item 10. The food composition according to Item 4-10, which is a tablet, capsule, powder, or granule.
Item 4-12. Item 10. The food composition according to Item 4-10, which is a beverage containing 0.005 to 25 w / v% of the tea flower part or 0.001 to 5 w / v% of the tea flower part extract in terms of dry weight.
Item 4-13. Item 10. The food composition according to Item 4-10, which is a supplement-type food containing 0.25 to 99% by weight of a tea flower part or 0.05 to 70% by weight of an extract of a tea flower part in terms of dry weight.
Item 4-14. Item 5. A pharmaceutical composition comprising the antifeedant according to Item 4-1 or 4-2, and a pharmaceutically acceptable carrier and / or additive.
Item 4-15. Item 15. The pharmaceutical composition according to Item 4-14, which is used for eating suppression.
Item 4-16. Item 16. The pharmaceutical composition according to Item 4-14 or 4-15, comprising 0.005 to 70% by weight of a tea flower part or 0.001 to 70% by weight of an extract of a tea flower part in terms of dry weight.
Item 4-17. Item 4-14 to 4-16, formulated to contain 0.5 to 25000 mg of cha flower or 0.1 to 5000 mg of tea flower extract in dry weight per daily dosage unit A pharmaceutical composition according to any one of the above.

This invention provides the invention of the aspect hung up below as a use regarding the reduction | decrease in blood cholesterol or neutral fat of the flower part of a tea, or its extract.
Item 5-1. An agent for reducing blood cholesterol or neutral fat, comprising tea flower or its extract as an active ingredient.
Item 5-2. Item 5. The blood cholesterol or neutral fat reducing agent according to Item 5-1, wherein the extract is an extract obtained by extracting the flower part of tea with water or a hydrous lower alcohol.
Item 5-3. A composition for reducing blood cholesterol or neutral fat, comprising tea flower or an extract thereof.
Item 5-4. Item 5. The composition for reducing blood cholesterol or neutral fat according to Item 5-3, which is a food composition or a pharmaceutical composition.
Item 5-5. Item 5-3, which is prepared to contain 0.5 to 25000 mg of tea flower part or 0.1 to 5000 mg of tea flower extract in terms of dry weight per daily intake unit or daily dosage unit The composition for reducing blood cholesterol or neutral fat according to 5-4.
Item 5-6. Item 15. A food composition comprising the blood cholesterol or neutral fat reducing agent according to Item 5-1 or 5-2, and a food material and / or food additive.
Item 5-7. Item 7. The food composition according to Item 5-6, which is used for reducing blood cholesterol or neutral fat.
Item 5-8. Item 8. The food composition according to Item 5-6 or 5-7, comprising 0.005 to 99% by weight of a tea flower part or 0.001 to 70% by weight of an extract of a tea flower part in terms of dry weight.
Item 5-9. Any of items 5-6 to 5-8, which is made to contain 0.5 to 25000 mg of tea flower or 0.1 to 5000 mg of tea flower extract in terms of dry weight per daily intake unit Food composition according to crab.
Item 5-10. Item 10. The food composition according to any one of Items 5-6 to 5-9, which is a beverage or a supplement type food.
Item 5-11. Item 11. The food composition according to Item 5-10, which is a tablet, capsule, powder, or granule.
Item 5-12. Item 11. The food composition according to Item 5-10, which is a beverage containing 0.005 to 25 w / v% of the tea flower part or 0.001 to 5 w / v% of the tea flower part extract in terms of dry weight.
Item 5-13. Item 10. The food composition according to Item 5-10, which is a supplement-type food containing 0.25 to 99% by weight of a tea flower part or 0.05 to 70% by weight of an extract of a tea flower part in terms of dry weight.
Item 5-14. Item 6. A pharmaceutical composition comprising the blood cholesterol or neutral fat reducing agent according to Item 5-1 or 5-2, and a pharmaceutically acceptable carrier and / or additive.
Item 5-15. Item 15. The pharmaceutical composition according to Item 5-14, which is used for reducing blood cholesterol or neutral fat.
Item 5-16. Item 15. The pharmaceutical composition according to Item 5-14 or 5-15, comprising 0.005 to 70% by weight of tea flower part or 0.001 to 70% by weight of tea flower extract in terms of dry weight.
Item 5-17. Item 5-14 to 5-16, formulated to contain 0.5 to 25000 mg of cha flower or 0.1 to 5000 mg of cha flower extract in dry weight per daily dosage unit A pharmaceutical composition according to any one of the above.

The present invention provides the following aspects of the invention for use in improving the metabolic syndrome of tea flower parts or extracts thereof.
Item 6-1. Metabolic syndrome improving agent comprising tea flower or its extract as an active ingredient.
Item 6-2. Item 6. The metabolic syndrome improving agent according to Item 6-1, wherein the extract is an extract obtained by extracting the flower part of tea with water or a hydrous lower alcohol.
Item 6-3. A composition for improving metabolic syndrome, comprising tea flower or an extract thereof.
Item 6-4. Item 6. The composition for improving metabolic syndrome according to Item 6-3, which is a food composition or a pharmaceutical composition.
Item 6-5. Item 6-3, which is manufactured to contain 0.5 to 25000 mg of tea flower part or 0.1 to 5000 mg of tea flower extract in terms of dry weight per daily intake unit or daily dosage unit The composition for improving metabolic syndrome according to 6-4.
Item 6-6. Item 7. A food composition comprising the metabolic syndrome improving agent according to Item 6-1 or 6-2, and a food material and / or food additive.
Item 6-7. Item 6. The food composition according to Item 6-6, which is used for improving metabolic syndrome.
Item 6-8. Item 8. The food composition according to Item 6-6 or 6-7, comprising 0.005 to 99% by weight of a tea flower part or 0.001 to 70% by weight of an extract of a tea flower part in terms of dry weight.
Item 6-9. Any one of Items 6-6 to 6-8, which is made to contain 0.5 to 25000 mg of tea flower or 0.1 to 5000 mg of tea flower extract in terms of dry weight per daily intake unit Food composition according to crab.
Item 6-10. Item 10. The food composition according to any one of Items 6-6 to 6-9, which is a beverage or a supplement type food.
Item 6-11. Item 10. The food composition according to Item 6-10, which is a tablet, capsule, powder, or granule.
Item 6-12. Item 10. The food composition according to Item 6-10, which is a beverage containing 0.005 to 25 w / v% tea flower part or 0.001 to 5 w / v% tea flower extract in terms of dry weight.
Item 6-13. Item 10. The food composition according to Item 6-10, which is a supplement-type food containing 0.25 to 99% by weight of a tea flower part or 0.05 to 70% by weight of an extract of a tea flower part in terms of dry weight.
Item 6-14. Item 7. A pharmaceutical composition comprising the metabolic syndrome improving agent according to Item 6-1 or 6-2, and a pharmaceutically acceptable carrier and / or additive.
Item 6-15. Item 15. The pharmaceutical composition according to Item 6-14, which is used for improving metabolic syndrome.
Item 6-16. Item 16. The pharmaceutical composition according to Item 6-14 or 6-15, comprising 0.005 to 70% by weight of tea flower part or 0.001 to 70% by weight of tea flower extract in terms of dry weight.
Item 6-17. Item 6-14 to 6-16, formulated to contain 0.5 to 25000 mg of cha flower or 0.1 to 5000 mg of cha flower extract in dry weight per daily dosage unit A pharmaceutical composition according to any one of the above.

According to the body fat reduction promoter of the present invention, reduction of body fat can be promoted, which is useful for eliminating obesity, reducing body fat percentage, and the like. Further, according to the lipid metabolism promoter of the present invention, lipid combustion can be promoted by promoting lipid metabolism, so obesity is eliminated, body fat percentage is reduced, blood neutral fat concentration is reduced. Useful for reduction. Furthermore, according to the preventive or therapeutic agent for hepatic disorder of the present invention, hepatic disorder such as fatty liver can be prevented or treated, which is useful for preventing or treating cirrhosis and hepatitis. And furthermore, according to the antifeedant of the present invention, it is possible to moderately suppress appetite due to the antifeeding effect, thereby suppressing excessive food consumption, so that obesity prevention, slimming maintenance, dieting, etc. Further, the body fat reduction promoter, lipid metabolism promoter, hepatic disorder preventive or therapeutic agent of the present invention, or feeding inhibitor, body fat reduction promotion, lipid metabolism promotion, liver disorder prevention or treatment, Since effects such as suppression of feeding, reduction of blood cholesterol or neutral fat can be exhibited comprehensively, it is also useful for improvement of metabolic syndrome.

  Furthermore, since the active ingredient used in the present invention is prepared by using the flower part of tea or this as a raw material, it is highly safe and can be provided in the form of food as well as pharmaceutical products.

  Body fat reduction promoter, lipid metabolism promoter, hepatic disorder preventive or therapeutic agent, antifeedant, blood cholesterol or neutral fat reducer, and metabolic syndrome improver (hereinafter referred to as these) (Simply referred to simply as “the agent of the present invention”) is characterized in that the flower part of tea or an extract thereof is used as an active ingredient.

  The flower part of the tea used in the present invention includes tea flowers, tea flower buds, and tea buds, including parts such as stamens, pistils, petals, flower axes, floral patterns, camellia, and leaves. Is done. In the present invention, as the cha flower part, any one of the whole or part of the cha flower, the whole or part of the flower bud, the whole or part of the bud may be used, and these may be mixed. You may use what you did.

Moreover, the flower part of the tea used in the present invention may be derived from wild species or derived from improved varieties. Specifically, examples of tea flower parts include, but are not limited to, Chinese var. Sinensis , Assam var. Assamica ( Mast. ) Kitam , and hybrids derived from these. In the active ingredient extraction material of the present invention, one kind of tea flower part may be used alone, or two or more kinds of tea flower parts may be used in combination.

  In the present invention, when the flower part of the tea itself is used as an active ingredient, the flower part of the tea may be used as it is collected, but may be subjected to treatments such as drying, shredding, and powdering as necessary. You may use what you did. In the case where the tea flower itself is used as an active ingredient, from the viewpoint of making the body fat reduction promoting effect, lipid metabolism promoting effect, prevention or treatment effect of liver damage, feeding suppression effect, etc. more prominently, It is desirable to use a dry powder of flower parts.

  Moreover, the tea flower part extract used as an active ingredient in the present invention can be obtained by solvent extraction of the tea flower part as a raw material.

  The flower part extract of tea can be produced according to a commonly used method for preparing a plant extract. Specifically, the extract of the flower part of the tea is extracted with a solvent after the flower part of the tea has been collected or subjected to processing such as drying, shredding, crushing as necessary. Can be obtained.

  Examples of the solvent used in the tea flower extraction process include water, an organic solvent, or a mixture of water and an organic solvent. Specific examples of the organic solvent used in this extraction treatment include lower alcohols having 1 to 5 carbon atoms such as methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, and t-butanol. However, it is not limited to these. The extraction solvent is preferably water or a mixed solution of lower alcohol and water having 1 to 5 carbon atoms (hydrated lower alcohol), more preferably water or a mixture of ethanol and water (hydrated ethanol), particularly preferably water. Can be mentioned. When a hydrous lower alcohol is used as the solvent, the content of the lower alcohol with respect to the total weight of the hydrous lower alcohol is, for example, more than 0 wt% and 80 wt% or less, preferably more than 0 wt% and 50 wt% or less, Preferably, it is more than 0% by weight and 30% by weight or less.

  For example, about 1 to 50 parts by weight of a solvent, preferably about 5 to 20 parts by weight of a solvent is added to 1 part by weight of the tea flower part, and the tea flower part is stirred as necessary. The reaction may be performed for several minutes to several days, preferably 30 minutes to 20 hours, more preferably about 1 hour to 10 hours. About temperature conditions at the time of extraction processing, what is necessary is just to set up suitably according to a kind etc. of a solvent, but usually 10-100 ° C, preferably 50-98 ° C, and more preferably 60-97 ° C is illustrated. Furthermore, the pressure conditions during the extraction treatment are not particularly limited, and may be normal pressure or pressurized conditions. The extraction process may be either batch type or reflux type.

  After performing the extraction process, the solid part is removed by solid-liquid separation means such as filtration or centrifugation, and the solution fraction is collected to obtain an extract of the tea flower part. Moreover, about the removed solid content, it may use for an extraction process again and an extract may be collect | recovered, and this can raise extraction efficiency.

  Thus, the extract of the flower part of the tea obtained by the extraction treatment is in a liquid state, and in the present invention, the extract can be used as it is. It is preferable to remove the organic solvent by distillation or the like. In the present invention, the tea flower part extract may be used in a liquid form, but if necessary, the moisture content is reduced by performing a drying process such as reduced pressure drying, freeze drying, spray drying or the like. By removing, it may be used in the form of concentrated liquid, semi-solid, solid or powder.

  The tea flower extract may be further purified by subjecting it to an appropriate purification treatment such as chromatography or solvent separation.

  The agent of the present invention may use any one of tea flower parts and extracts thereof as an active ingredient, or a combination thereof. The tea flower extract is concentrated in a high concentration of components that contribute to the promotion of body fat reduction, the effect of promoting lipid metabolism, the prevention or treatment of liver damage, or the effect of suppressing feeding. And can be applied to compositions of various forms, and is suitable as an active ingredient used in the present invention.

  The agent of the present invention is used for uses such as promotion of reduction of body fat, promotion of lipid metabolism, prevention or treatment of liver damage, or suppression of eating. Specifically, according to the body fat reduction promoter of the present invention, it is possible to promote lipid metabolism and promote reduction of body fat (particularly combustion of accumulated body fat). It can be used for applications such as rate reduction. Moreover, according to the lipid metabolism promoter of the present invention, lipid metabolism can be promoted to enhance lipid combustion, which is useful for applications such as elimination of obesity, reduction of body fat percentage, and reduction of blood neutral fat concentration. It is. Moreover, according to the preventive or therapeutic agent for hepatic disorder of the present invention, hepatic disorder such as fatty liver can be prevented or treated, which is useful for the use such as prevention or treatment of cirrhosis or hepatitis. The liver disorder mentioned here may be a liver disorder such as fatty liver induced by obesity, or a liver disorder such as fatty liver induced by excessive alcohol intake such as excessive drinking. . Furthermore, according to the antifeedant of the present invention, it is possible to suppress appetite moderately due to an antifeeding effect, thereby suppressing excessive food consumption, and thus, for obesity prevention, maintenance of slimming, dieting, etc. Useful for.

  Moreover, the active ingredient used by this invention has the effect | action which reduces blood cholesterol and a triglyceride density | concentration. Therefore, the above active ingredient is also useful as a blood cholesterol or neutral fat reducing agent. In particular, the reducing agent is blood cholesterol or neutrality for humans with high cholesterol levels or neutral fat levels (for example, humans who have been diagnosed with high cholesterol levels or triglyceride levels in past medical examinations). Useful as a fat reducing agent.

  Furthermore, useful effects of the above active ingredients, such as promoting body fat reduction, promoting lipid metabolism, preventing or treating liver damage, suppressing feeding, reducing blood cholesterol or neutral fat, etc. It is effective for improvement. Therefore, the active ingredient is also useful as an agent for improving metabolic syndrome.

The agent of the present invention is used in the form of oral intake or oral administration. The intake or dose of the agent of the present invention differs depending on the type of active ingredient, the age or weight of the intake or administration subject, symptoms, expected effects, etc., and cannot be defined uniformly. The following ranges are exemplified as daily intake (daily intake unit) or adult daily dose (daily dosage unit):
When the active ingredient is tea flower itself : 0.5 to 25000 mg, preferably 5 to 15000 mg, more preferably 50 to 5000 mg.
When the active ingredient is a tea flower extract : 0.1 to 5000 mg, preferably 1 to 3000 mg, more preferably 10 to 1000 mg, in terms of dry weight of the extract itself.

  In addition, as the daily intake or administration frequency of the agent of the present invention, the intake or dose per administration, the daily intake unit or daily administration unit, the form of the agent, etc. are comprehensively considered as appropriate. What is necessary is just to set, but normally 1 time or several times, Preferably it is 1-3 times, More preferably, it is 1-2 times.

  As described above, the agent of the present invention can have a desired effect by being orally ingested or administered orally as described above. Therefore, the agent of the present invention is used in the field of food or medicine. It may be used as an agent or a pharmaceutical additive. In addition, the agent of the present invention may be used alone for the various uses described above, but the food material (food carrier), food additive, pharmaceutically acceptable carrier, pharmaceutically acceptable It is desirable to be provided in the form of a composition mixed with other ingredients such as additives. Thus, the composition containing the agent of the present invention is used as a composition for promoting body fat reduction, a composition for promoting lipid metabolism, a composition for preventing or treating liver damage, or a composition for suppressing eating. Furthermore, the composition containing the agent of the present invention can also be used as a composition for reducing blood cholesterol or neutral fat, or a composition for improving metabolic syndrome.

  In the above composition, the components used in combination with the agent of the present invention are specifically excipients, binders, disintegrants, lubricants, moisture-proofing agents, preservatives, thickeners, emulsifiers, and wetting agents. Examples include agents, buffers, diluents, antioxidants, sweeteners, acidulants, seasonings, colorants, fragrances, etc., but food materials, food additives, pharmaceutically acceptable carriers, or pharmaceuticals It is not limited as long as it can be used as an acceptable additive.

  Moreover, the said composition can also mix | blend the well-known raw material used for the prevention or treatment of obesity, a diet, or slimming with the agent of this invention. Such materials include, for example, plants such as Garcinia cambodia peel extract, grape seed extract, fruit polyphenols such as apples, yamakoko fruit extract, guava leaf extract, gymnema sylvesta leaf extract, ginkgo biloba extract, hoodia gordonii extract, etc. Examples include extracts; enzyme inhibitors such as lipase inhibitors and α- and β-amylase inhibitors; L-cartinine; algal extracts such as green algae extract and brown algae extract.

  In the composition containing the agent of the present invention, the blending ratio of the agent of the present invention varies depending on the form of the composition, the type of active ingredient, the age or sex of the subject of intake or administration, the expected effect, etc. For example, when the active ingredient is the tea flower part itself, 0.005 to 99% by weight, and when the active ingredient is the tea flower part extract, 0.001 to 70% by weight in terms of dry weight can be mentioned. The mixing ratio of the agent of the present invention in the composition includes the daily intake unit or daily dose unit of the agent of the present invention described above per total daily intake or total dose of the composition. It is desirable to be set so that

  Examples of preferred forms of the composition containing the agent of the present invention include food compositions and pharmaceutical compositions. Hereinafter, specific embodiments of the food composition and the pharmaceutical composition will be described.

  The food composition containing the agent of the present invention is mixed with a food material (food carrier) and / or a food additive together with the agent of the present invention, depending on the form of the target food composition, if necessary. It is prepared by performing various treatments (heating, cooling, molding, etc.). Since the food composition has a useful action based on the agent of the present invention, it is provided not only as a general food, but also as a food for specified health use, a dietary supplement, a functional food, a food for the sick, etc. The In particular, the food composition is useful as a food provided for the purpose of promoting body fat reduction, promoting lipid metabolism, preventing or treating liver damage, or suppressing feeding. The food composition is also useful as a food provided for the purpose of reducing blood cholesterol or neutral fat or improving metabolic syndrome. Moreover, in specific embodiment, the food composition of this invention may be provided as a foodstuff which attached | subjected the display to the effect that it is used for the above uses.

  As a preferred form of the food composition, drinks such as nutritional drinks, soft drinks, and milk drinks; supplement-type foods such as tablets, capsules, powders, and granules; confectionery such as cereals, baked goods, and jelly Etc. are exemplified. Among such forms of food, beverages and supplement-type foods can contain the agent of the present invention at a high concentration, so even if the daily intake of food is set to a small amount, the desired effect is sufficiently obtained. This is preferable because it can be played.

  In the food composition, the blending ratio of the agent of the present invention can be appropriately set according to the type of the food composition, the type of active ingredient, the age, sex, expected effect, etc. of the ingested person. it can. As an example of the blending ratio of the agent of the present invention relative to the total weight of the food composition, when the active ingredient is the flower part of the tea itself, 0.005 to 99% by weight, preferably 10 to 75% by weight; In the case of the flower part extract, 0.001 to 70% by weight, preferably 2 to 50% by weight, in terms of dry weight.

From the viewpoint that the useful effect based on the agent of the present invention is more effectively exhibited by ingesting the food composition, the blending ratio of the agent of the present invention in the food composition is the form of the food composition, 1 In consideration of the number of daily intakes and the like, it is desirable that the daily intake unit of the agent of the present invention described above be included per total daily intake of the food composition. Specifically, as such a blending ratio, the following ranges are exemplified in the case of beverages and supplement-type foods:
For beverages : If the active ingredient is the flower part of the tea itself, it is usually 0.005 to 25 w / v%, preferably 0.025 to 25 w / v%, more preferably 10 to 25 w / v%; Is usually 0.001 to 5 w / v%, preferably 0.005 to 5 w / v%, more preferably 2 to 5 w / v% in terms of dry weight.
In the case of supplement type food : If the active ingredient is the flower part of the tea itself, it is usually 0.25 to 99% by weight, preferably 0.5 to 99% by weight, more preferably 10 to 75% by weight; The extract is usually 0.05 to 70% by weight, preferably 0.1 to 60% by weight, and more preferably 2 to 50% by weight in terms of dry weight.

  Moreover, the pharmaceutical composition containing the agent of this invention is prepared by mix | blending a pharmaceutically acceptable carrier and / or additive with the agent of this invention, and shape | molding in a desired form. Since the pharmaceutical composition has a useful action based on the agent of the present invention, it is useful as a pharmaceutical for promoting body fat reduction, promoting lipid metabolism, preventing or treating liver damage, or suppressing feeding. is there. Furthermore, the pharmaceutical composition is useful as a medicament for reducing blood cholesterol or neutral fat, or for improving metabolic syndrome.

  Although it does not restrict | limit especially about the form of this pharmaceutical composition, A liquid agent, a powder, a tablet, a granule, a capsule, a syrup agent, a troche agent etc. are illustrated.

  In the pharmaceutical composition, the blending ratio of the agent of the present invention is set so that the above-mentioned daily dosage unit of the agent of the present invention is included per total daily dose of the pharmaceutical composition. It is often set as appropriate according to the type of the pharmaceutical composition, the type of active ingredient, the age, sex, expected effect, etc. of the administration subject. As an example, the blending ratio of the agent of the present invention with respect to the total weight of the pharmaceutical composition is 0.005 to 70% by weight, preferably 10 to 50% by weight when the active ingredient is the flower part of the tea itself; In the case of a tea flower extract, 0.001 to 70% by weight, preferably 2 to 50% by weight, in terms of dry weight can be mentioned.

  Hereinafter, the present invention will be described in detail based on examples and the like, but the present invention is not limited to these examples.

Reference Example 1 Preparation of Cha Flower Part Extract To 150 kg of tea flower part, 13 times amount (weight ratio) of hot water at 95 ° C. was added and immersed for 120 minutes while being kept at 95 ° C. for extraction treatment. After the extraction treatment, a solid content and a liquid content (hereinafter referred to as a first extract) were separated by filtration. Subsequently, 11 times amount (weight ratio) of 95 ° C. hot water was again added to the recovered solid content, and extraction treatment was performed by dipping for 10 minutes while maintaining the temperature at 95 ° C. After the extraction treatment, a solid content and a liquid content (hereinafter referred to as a second extract) were separated by filtration. The first extract and the second extract thus collected were mixed and concentrated to about 160 L with a vacuum concentrator (concentration temperature 40-50 ° C., vacuum degree 2.7-21.3 kPa). The concentrated liquid thus obtained was dried with a spray drying apparatus (inlet temperature 140 ° C., outlet temperature 90 ° C., atomizer rotational speed 16000 rpm) to obtain 35.5 g of powdered tea flower part extract. .

Test Example 1 Adipocyte Differentiation Inhibition Test Rat visceral adipose precursor cells (Primary Cell Co., Ltd.) were seeded in a 96-well culture plate at about 2500 cells / well, and the visceral fat of Visceral Adipocyte Culture Kit (Primary Cell Co., Ltd.) Using differentiation medium as a medium, the cells were cultured at 37 ° C. under 5% CO ₂ for 3 days. Thereafter, the tea flower part extract obtained in Reference Example 1 was added to the culture plate to a concentration of 0.1 or 1.0 mg / mL, and further cultured at 37 ° C. under 5% CO ₂ for 5 days. In addition, as a control, rat visceral adipose precursor cells were cultured under the same conditions as above except that no cha flower extract was added. After completion of the culture, the nuclei of differentiated adipocytes were stained with Hoechst 33258 (DOJINDO), the lipid droplets were stained with BODIPY 493/503 (Invitrogen), and the fluorescence values of each were digitized with In cell Analyzer 1000 (GE). The measured average area of fat droplets per cell was used as an index of adipocyte differentiation, and the measured number of living cells was used as an index of toxicity.

  FIG. 1 shows the results of the average area of fat droplets per cell and the number of living cells. From this result, it became clear that the lipid droplet area was significantly reduced and the differentiation of adipocytes was suppressed by adding the extract of the present invention. In addition, when the change in the number of living cells was observed as an indicator of toxicity, no significant decrease in the number of cells was observed due to the addition of the extract of the present invention, and the extract of the flower part of Cha showed no cytotoxicity and was safe. It was also confirmed that it could be used.

Test Example 2 Lipid Droplet Metabolism Test Using Adipocytes In order to examine the fat metabolism effect of the tea flower part extract obtained in Reference Example 1, the following test was conducted. First, rat visceral fat progenitor cells (Primary Cell Co., Ltd.) are seeded in a 96-well culture plate at about 2500 cells / well, and the visceral fat differentiation medium of Visceral Fat Cell Culture Kit (Primary Cell Co., Ltd.) is used as the medium. Then, the cells were cultured for 7 days under conditions of 37 ° C. and 5% CO ₂ to differentiate into adipocytes that accumulated a sufficient amount of fat. Thereafter, the tea flower part extract obtained in Reference Example 1 was added to the culture plate so as to have a concentration of 0.1 or 1.0 mg / mL, and further cultured at 37 ° C. under 5% CO ₂ for 12 hours. Thereafter, the concentration of glycerol secreted into the culture solution was measured using an Adipocyte Lipolysis kit (Zen Bio), and used as an index of lipid droplet metabolism.

  FIG. 2 shows the measurement result of the glycerol concentration. From this result, it was clarified that by adding the tea flower extract, glycerol release from adipocytes was remarkably increased, and fat metabolism in adipocytes was enhanced.

Test Example 3 Body fat reduction effect test using obese model rats (1)
SD rats (male 4 weeks old) that had been acclimatized for 5 days were divided into groups using body weight as an index so that each group was equalized. During the experimental period, the control group feed was the low-fiber high-fat feed shown in Table 1 below (containing 0.4% fiber and 30% beef tallow), and the cha flower extract administration group had a concentration of 0.5% or 5% by weight. A feed was prepared by blending the tea flower extract obtained in 1 with the low-fiber high-fat feed, and was bred by pair feeding. After 22 days of breeding, the animals were fasted overnight and dissected to remove subcutaneous fat and visceral fat (cold testicular fat, retroperitoneal fat, intestinal membrane fat, perirenal fat). The weight of subcutaneous fat was measured, and the percentage of subcutaneous fat (%) was calculated as the ratio of the weight of subcutaneous fat per body weight of the rat. Moreover, the weight of the visceral fat was measured, and the ratio of the visceral fat weight per body weight of the rat was calculated as the visceral fat ratio (%).

  FIG. 3 shows the measurement result of the subcutaneous fat percentage, and FIG. 4 shows the measurement result of the visceral fat percentage. From this result, in the group fed with the feed containing the tea flower part extract, a significant decrease was observed in both the subcutaneous fat rate and the visceral fat rate. From the above results, it has been clarified that the tea flower extract contains a component useful for promoting the reduction of body fat or the promotion of lipid metabolism.

Test Example 4 Body fat reduction effect test using obese model mice (2)
C57BL / 6J mice (4 weeks old male) that had been acclimatized for 3 days were fed with a high fat diet (Research Diet D12492: diet containing 60% kcal fat) and reared. Two weeks after feeding the high-fat diet, the groups were divided into three groups using the body weight as an index so that the average body weight of each group was equal. For each group, high-fat diet, low-fat diet (manufactured by Clea Japan Co., Ltd., CE-2: 12.4% kcal fat), 3% by weight of the cha flower extract obtained in Reference Example 1 A low fat diet (CE-2) formulated as described above was given. After 10 days of breeding, the animals were fasted overnight, dissected and blood was collected from the abdominal vena cava, and subcutaneous fat and visceral fat (cold testicular fat, retroperitoneal fat, mesenteric fat, perirenal fat) were removed. The weight of subcutaneous fat was measured, and the percentage of subcutaneous fat (%) was calculated as the ratio of the weight of subcutaneous fat per body weight of the mouse. Moreover, the weight of the visceral fat was measured, and the ratio of the visceral fat weight per body weight of the mouse was calculated as the visceral fat ratio (%). In addition, total cholesterol and neutral fat (triglyceride) in plasma after blood centrifugation was measured.

  FIG. 5 shows the measurement result of subcutaneous fat percentage, FIG. 6 shows the measurement result of visceral fat percentage, FIG. 7 shows the measurement result of plasma total cholesterol concentration, and FIG. 8 shows the measurement result of plasma neutral fat (triglyceride) concentration. Indicates. From this result, in the group fed with the diet containing tea flower part extract, all the measurement items of subcutaneous fat rate, visceral fat rate, plasma total cholesterol concentration, and plasma neutral fat concentration are remarkable. A decrease was observed. From the above results, it has been clarified that the extract of the flower part of tea contains components useful for promoting the reduction of accumulated body fat or promoting lipid metabolism.

Test Example 5 Liver Protective Effect Test The cha flower extract obtained in Reference Example 1 at 100 or 500 mg per 1 kg of rat was orally administered to SD rats (5 weeks old male) after 7 days of quarantine acclimatization. Thereafter, 1000 mg of DL-ethionine (WAKO) per kg of rat was intraperitoneally administered to try to induce fatty liver in the rat. One day after the administration of DL-ethionine, 100 mg or 500 mg of cha flower extract per kg of the rat was orally administered once a day for a total of 2 days. During the experiment, a low-fat diet (CE-2) was freely consumed. After the final administration, the rats were fasted, and serum was collected 16 hours after the final administration, and GOT (glutamate oxaloacetate transaminase) in the serum was measured with Fuji Dry Chem (FUJIFILM).

  The results are shown in FIG. As a result, a decrease in GOT was confirmed depending on the dose of tea flower extract. From the above, it has been clarified that the tea flower extract contains components useful for liver protection, and the tea flower extract is useful for the prevention or treatment of liver damage.

Test example 6 Feeding inhibitory effect test C57BL / 6J mice (male 5 weeks old) after 7 days of quarantine habituation were divided into groups using body weight as an index, and each group was equalized for 2 months. Fat feed (Research Diet D12492: feed containing 60% kcal fat) was fed and reared. During the breeding period, 500 mg of the cha flower extract obtained in Reference Example 1 per 1 kg of the mouse was orally administered once a day. In the control group, the same volume of distilled water (Otsuka Pharmaceutical) was orally administered. Mice feed intake during the oral administration period was measured once a week and continued until the end of the study.

  The obtained result is shown in FIG. From this result, the total feed intake per mouse for two months was clearly decreased in the cha flower extract administration group. From the above, it has been clarified that the tea flower extract contains a component that suppresses the amount of feed consumed, and the tea flower extract is useful for suppressing food intake.

Formulation Examples Formulation examples are given below, but the present invention is not limited thereto. In addition, what was manufactured by the said reference example 1 is used for the tea flower part extract used in the following formulation examples.

Formulation Example 1 Tablet (1 tablet 280 mg)
Tea flower part extract 100mg
Crystalline cellulose 168mg
Sucrose fatty acid ester 9mg
Fine silicon dioxide 3mg
280mg total
A tablet is produced according to a conventional method so as to contain the above blending amount per tablet. This tablet is taken 1 tablet at a time, 3 times a day.

Formulation Example 2 Film-coated tablets (1 tablet 250 mg)
Tea flower part powder 25mg
Caffeine 12.5mg
Theanine 25mg
Lactose appropriate amount Corn starch 57mg
Calcium stearate 5mg
Shellac 3mg
Carnauba wax
250mg total
Film-coated tablets are produced according to a conventional method so as to contain the above-mentioned blending amount per tablet. These tablets are taken 4 times a day, 3 times a day as a guide.

Formulation Example 3 Chewable tablets (1 tablet 850 mg)
Tea flower part extract 50mg
Green tea powder 50mg
Reduced maltose starch syrup 707mg
Fine silicon dioxide 10mg
Sucrose fatty acid ester 30mg
Fragrance 3mg
850mg total
Chewable tablets are produced according to a conventional method so as to include the above-mentioned blending amount per tablet. These tablets are taken 2 times at a time, 3 times a day as a guide.

Formulation Example 4 Chewable tablets (1 tablet 1000 mg)
Tea flower part powder 10mg
Erythritol 280mg
Xylitol 280mg
Crystalline cellulose 280mg
Hoodia Gordonie 100mg
Calcium stearate 30mg
Fragrance 20mg
1000mg total
Chewable tablets are produced according to a conventional method so as to include the above-mentioned blending amount per tablet. These tablets are taken 2 times at a time, 3 times a day as a guide.

Formulation Example 5 Chewable tablets (1 tablet 180mg)
Tea flower part extract 1mg
Vitamin C 10mg
Sorbitol appropriate amount Sucralose 0.3mg
Sucrose fatty acid ester 3mg
l-Menthol 2mg
Fragrance 3mg
180mg total
Chewable tablets are produced according to a conventional method so as to include the above-mentioned blending amount per tablet. These tablets are taken 4 times a day, 3 times a day as a guide.

Formulation Example 6 Soft capsule (1 capsule 440 mg)
Tea flower part extract 120mg
Evening primrose oil 50mg
Safflower oil 30mg
Beeswax 30mg
Glycerin fatty acid ester 30mg
Soft capsule skin 180mg
440mg total
A soft capsule is prepared according to a conventional method so as to contain the above-mentioned blending amount per tablet. This soft capsule is ingested 3 times a day with 1 capsule at a time.

Formulation Example 7 Fruit juice beverage (100ml each)
Cha flower part extract 3g
Fructose glucose liquid sugar 16g
Citric acid 0.25g
Grapefruit concentrated juice 2.3g
Fragrance 0.8g
Appropriate amount of water
100mL total
A juice drink is produced according to a conventional method so as to include the above-mentioned blending amount per one. This fruit juice drink is taken on a daily basis.

Formulation Example 8 Soft Drinks (200ml each)
Cha flower extract 0.05g
Fructose glucose liquid sugar 20g
Sucralose 0.005g
Citric acid 0.4g
Trisodium citrate 0.1g
Fragrance 0.2g
Appropriate amount of water
200mL total
A soft drink is produced according to a conventional method so as to include the above-mentioned blending amount per one. This soft drink is taken on a daily basis.

Formulation Example 9 Green tea beverage (500ml each)
Tea leaf part (green tea) 3g
Tea flower part (chopped) 1g
Vitamin C 0.1g
Appropriate amount of water
500 mL total
After the tea leaves and tea flowers are boiled with hot water so as to have the above amount, they are sufficiently cooled, and vitamin C is added to produce a green tea beverage. This green tea drink is taken on a daily basis.

Formulation Example 10 Jelly (20g each)
Cha flower part extract 0.01g
Erythritol 3g
0.01g sweetener
Gelling agent 1.5g
Citric acid 0.06g
Trisodium citrate 0.04g
Fragrance 0.1g
Appropriate amount of water
20g total
A jelly is produced according to a conventional method so as to include the above blending amount per one. This jelly is ingested on a daily basis for three.

Formulation Example 11 Diet Bar (20g each)
Tea flower part extract 0.04g
Eggshell calcium 0.5g
Vitamin B1 0.6mg
Vitamin B2 0.4mg
Niacin 7mg
Iron 8mg
Light flour flour appropriate amount Granulated sugar 4.5g
Margarine 5g
1g yolk
0.05g salt
Perfume 0.04g
Appropriate amount of water
20g total
A bar is produced according to a conventional method so as to include the above blending amount per one. This bar is taken on a daily basis.

In Experiment 1, it is a figure which shows the result of having measured the average area of the lipid droplet per fat cell after adding the flower part extract of a tea, and the number of living cells. In the figure, the bar graph shows the average area of lipid droplets (μm ² / cell), and the line graph shows the number of living cells. In Experiment 2, it is a figure which shows the result of having measured the glycerol density | concentration secreted in the culture solution, after adding the flower part extract of the tea to the fat cell which accumulated sufficient fat mass. In Experiment 3, it is a figure which shows the result of having measured the subcutaneous fat rate of the rat after feeding the flower part extract of the tea to the obese model rat. In Experiment 3, it is a figure which shows the result of having measured the visceral fat rate of a rat after feeding the flower part extract of a tea to an obese model rat. In Test Example 4, after feeding a high-fat diet (HFD), a low-fat diet (CE2), or a low-fat diet (CE2 + cha-flower part extract 3%) containing a cha flower extract, It is a figure which shows the result of having measured the subcutaneous fat rate of the mouse | mouth. In the figure, the high-fat diet administration group is `` HFD '', the low-fat diet administration group is `` CE2 '', and the low-fat diet administration group containing the tea flower extract is `` CE2 + cha flower part extract 3% '' Is written. In Experiment 4, it is a figure which shows the result of having measured the visceral fat rate of a mouse | mouth after feeding the low fat diet which mix | blended the high fat diet, the low fat diet, or the extract of the flower part of a tea to a mouse | mouth. In the figure, the high fat diet administration group is `` HFD '', the low fat diet administration group is `` CE2 '', and the low fat diet administration group containing tea flower extract is `` CE2 + Cha florescence extract 3% '' Is written. In Experiment 4, it is a figure which shows the result of having measured the total cholesterol density | concentration in the plasma of a mouse | mouth after feeding the low fat diet which mix | blended the high fat diet, the low fat diet, or the extract of the flower part of a tea to a mouse | mouth. is there. In the figure, the high fat diet administration group is `` HFD '', the low fat diet administration group is `` CE2 '', and the low fat diet administration group containing tea flower extract is `` CE2 + Cha florescence extract 3% '' Is written. In Test Example 4, the result of measuring the neutral fat (triglyceride) concentration in the plasma of a mouse after feeding the mouse with a low fat diet containing a high fat diet, a low fat diet, or a tea flower extract. FIG. In the figure, the high fat diet administration group is `` HFD '', the low fat diet administration group is `` CE2 '', and the low fat diet administration group containing tea flower extract is `` CE2 + Cha florescence extract 3% '' Is written. In Experiment 5, it is a figure which shows the result of having measured GOT in the serum of the rat which did not give the cha flower part extract, and the rat which gave 100 mg or 500 mg of the cha flower part extract per kg body weight. In Experiment 6, it is a figure which shows the result of having measured the feed intake of the mouse | mouth (control group) orally administered with distilled water, and the mouse | mouth (cha flower part extract administration group) orally administered the tea flower part extract.

Claims (6)

  A body fat reduction promoter comprising tea flower or its extract as an active ingredient.   The body fat reduction-promoting agent according to claim 1, which is for reducing accumulated body fat.   A lipid metabolism promoter comprising tea flower or an extract thereof as an active ingredient.   A preventive or therapeutic agent for liver damage, comprising tea flower or its extract as an active ingredient.   An antifeedant containing tea flower or its extract as an active ingredient.   The agent according to any one of claims 1 to 5, wherein the extract is an extract obtained by extracting a flower part of tea with water or a hydrous lower alcohol.

Images